Creative BioMart to Present at IMMUNOLOGY2024™|May 3-7, 2024|Booth #512 Learn More

NHLRC2

Official Full Name

NHL repeat containing 2
Synonyms

NHLRC2; NHL repeat containing 2; NHL repeat-containing protein 2; DKFZp779F115; FLJ20147; FLJ25621; FLJ33312; MGC45492; 1200003G01Rik; Novel NHL repeat domain containing protein; OTTHUMP00000020518;

Species	Cat.#	Product name	Source (Host)	Tag	Price
Human	NHLRC2-1193HCL	Recombinant Human NHLRC2 cell lysate		N/A	Inquiry
Mouse	Nhlrc2-4414M	Recombinant Mouse Nhlrc2 Protein, Myc/DDK-tagged	HEK293T	Myc/DDK	Inquiry
Chicken	NHLRC2-1643C	Recombinant Chicken NHLRC2	Mammalian Cell	His	Inquiry

Involved Pathway
Protein Function
Interacting Protein
NHLRC2 Related Articles

NHLRC2 involved in several pathways and played different roles in them. We selected most pathways NHLRC2 participated on our site, such as , which may be useful for your reference. Also, other proteins which involved in the same pathway with NHLRC2 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.

Pathway Name	Pathway Related Protein

NHLRC2 has several biochemical functions, for example, protein binding. Some of the functions are cooperated with other proteins, some of the functions could acted by NHLRC2 itself. We selected most functions NHLRC2 had, and list some proteins which have the same functions with NHLRC2. You can find most of the proteins on our site.

Function	Related Protein
protein binding	RIBC2;H3F3B;MAP2K5;CSRP2;AKAP8L;PINK1;IKZF2;VSTM2L;SPATA7

NHLRC2 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with NHLRC2 here. Most of them are supplied by our site. Hope this information will be useful for your research of NHLRC2.

CEP76

Brackmann, FA; Kiefer, A; et al. Rapidly Progressive Phenotype of Lafora Disease Associated With a Novel NHLRC1 Mutation. PEDIATRIC NEUROLOGY 44:475-477(2011).

Oki, Y; Ogura, M; et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. CANCER SCIENCE 99:179-184(2008).